Newland Pharmaceutical Co., Ltd. (SHE:301277)

China · Delayed Price · Currency is CNY

12.81

+0.13 (1.03%)

At close: Feb 27, 2026

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Pharmaceutical Intermediates	719.43M	643.85M	621.21M	508.93M	433.12M
Pharmaceutical Intermediates Growth	11.74%	3.64%	22.06%	17.50%	6.54%
Unallocated Other	7.00M	7.59M	6.15M	4.91M	-
Unallocated Other Growth	-7.70%	23.34%	25.30%	-	-
Total	726.44M	651.44M	627.36M	513.84M	433.12M
Total Growth	11.51%	3.84%	22.09%	18.64%	6.54%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2019	FY 2018
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
China	710.23M	641.16M	611.27M	500.11M	408.40M
China Growth	10.77%	4.89%	22.23%	22.45%	5.54%
Foreign	16.21M	10.28M	16.10M	13.73M	24.72M
Foreign Growth	57.71%	-36.15%	17.28%	-44.47%	26.31%
Total	726.44M	651.44M	627.36M	513.84M	433.12M
Total Growth	11.51%	3.84%	22.09%	18.64%	6.54%

Source: S&P Global Market Intelligence.